We participate in numerous events promoting our portfolio companies and meeting our clients.


Avexxin, a VP portfolio company focused on development of anti-inflammatory drugs, raises additional USD 2.5M from existing shareholders. Avexxin achieved Proof-of-Concept in man in a second phase I/IIa trial mid-2015.

RhoVac, a VP portfolio company developing a therapeutic cancer vaccine to eliminate metastases, raises an undisclosed amount in a pre-IPO round. The company is headed for public listing in Sweden early 2016.

Idogen, a VP portfolio company, starts collaboration with the Karolinska Institute in the development of tolerogenic vaccines based on reprogramming of human white blood cells. For more information, please visit www.idogen.com.

Idogen, a VP portfolio company, starts "proof of concept"-study for hemophilia to obtain orphan drug designation after a consultative meeting with the European Medicines Agency (EMA). For more information, please visit www.idogen.com.

Avexxin, a VP portfolio company, announced that its lead compound AVX001 in a topical formulation has shown Proof-of-Concept in man in an ascending dose Phase I/IIa study encompassing 26 patients suffering from mild-to-moderate psoriasis. A copy of Avexxin's press release providing details of the study is available at the following link.

Trading in Idogen AB's (”Idogen”) shares and warrants of series TO 1 begins on AktieTorget. This follows a 304% oversubscription observed in May indicating a strong interest from shareholders,

APIM Therapeutics, a VP portfolio company, announced that it has completed a new financing round by existing and new investors. This financing will enable the company to finalize preclinical development of ATX-101 aiming to file two clinical trial applications in late 2015.

Ventac Partners manages a successful FDA pharmaceutical audit of the manufacturing facility of a European client commercializing a series of non-sterile prescription and OTC drugs globally.

Subscribe to our Newsletter

Thank you!